Affiliation:
1. Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University
2. Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University
3. Nanjing Drum Tower Hospital, Nanjing University Medical School
Abstract
Abstract
Purpose
Immunoglobulin superfamily 6 (IGSF6) is a novel member of the immunoglobulin superfamily, and the association of IGSF6 with the prognosis and antitumor immune response in lung adenocarcinoma (LUAD) remains unknown. Here, we aim to identify the role of IGSF6-mediated immune signature in the prognosis and immune landscape of LUAD.
Methods
IGSF6 expression in pan-cancer and LUAD data from The Cancer Genome Atlas (TCGA) was analyzed by TIMER2.0 and GEPIA2, respectively. Quantitative-real-time-PCR (qRT-PCR), western blot, and immunohistochemistry (IHC) staining were performed to confirm the results of bioinformatics. The association of IGSF6 expression and promoter methylation levels with major clinical features was analyzed by using UALCAN. Survival curves were used to assess the connection between IGSF6 expression and LUAD prognosis. The enrichment analysis was conducted by running the R software clusterProfiler package. TISIDB and TIMER2.0 were utilized to investigate the correlation between IGSF6 and tumor-infiltrating lymphocytes (TILs) in LUAD. Human Protein Atlas (HPA) and flow cytometry (FCM) were used to confirm IGSF6 localization in macrophages.
Results
IGSF6 levels were decreased in LUAD, and methylation levels at the IGSF6 promoter in LUAD samples increased compared to that in peritumor samples, implying a potential mechanism that leads to the aberrant expression of IGSF6 in LUAD. Low IGSF6 expression was significantly related to poor survival. In addition, IGSF6 expression was closely associated with gene sets involved in immune cell proliferation and exogenous antigen presentation, and it was positively related to immune infiltrates with antitumor activity, including M1 macrophages, dendritic cells (DCs), and T helper 1 (Th1). Furthermore, the IGSF6 protein was mainly located on the membrane of macrophages in LUAD, which enabled exogenous antigen presentation by macrophages to enhance the antitumor immune response.
Conclusion
IGSF6 is a biomarker of LUAD and IGSF6-mediated immune signature determines the prognosis and immune landscape of LUAD.
Publisher
Research Square Platform LLC
Reference31 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J. Clin.,2021
2. R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer Stat. 2021 CA Cancer J Clin 71, 7–33 (2021)
3. Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis;Li MY;Mol. Cancer,2021
4. The 2021 Global Lung Cancer Therapy Landscape;Deb D;J. Thorac. Oncol.,2022
5. Lung cancer;Brody H;Nature.,2020